You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股消息》《新股消息》真實生物科技通過上市聆訊
阿思達克 08-05 09:25
內地創新藥研發公司「真實生物科技」通過上市聆訊並上載初步招股文件,其核心產品阿茲夫定為具有廣譜抗病毒活性的創新藥物,已分別於去年7月及今年7月獲國家藥監局附條件批准用於治療愛滋病患者及新型冠狀病毒肺炎。 今年首五個月公司虧損2.18億元人民幣(下同),去年同期虧損6,867.4萬元,上市集資所得將用於阿茲夫定治療治療愛滋病患者、HFMD及若干類型血液腫瘤的臨床開發、阿茲夫定治療新型冠狀病毒肺炎的製造及商業化、臨床前或IND階段候選藥物的臨床開發,以及加強研發平台與擴大產品管線等。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account